Edwards Lifesciences (CH:EW)

:EW

Edwards Lifesciences

RESEARCH TOOLSreports

Want to see CH:EW full AI Analyst Report?

Edwards Lifesciences (EW) Stock Forecast & Price Target

2 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

EW Analyst Ratings

Moderate Buy

16 Buy

6 Hold

0 Sell

Based on 22 analysts giving stock ratings to

Edwards

Lifesciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

EW Stock 12 Month Forecast

Average Price Target

CHF75.59

▲(9.92% Upside)

Based on 22 Wall Street analysts offering 12 month price targets for Edwards Lifesciences in the last 3 months. The average price target is CHF75.59 with a high forecast of CHF86.19 and a low forecast of CHF67.39. The average price target represents a 9.92% change from the last price of CHF68.77.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"66":"CHF66","87":"CHF87","71.25":"CHF71.3","76.5":"CHF76.5","81.75":"CHF81.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":86.1904824,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF86.19</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":75.5890530648,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF75.59</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67.38528624,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF67.39</span>\n  </div></div>","useHTML":true}}],"tickPositions":[66,71.25,76.5,81.75,87],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,68.772,70.11188326153847,71.45176652307693,72.79164978461539,74.13153304615385,75.47141630769231,76.81129956923077,78.15118283076923,79.49106609230769,80.83094935384615,82.17083261538461,83.51071587692307,84.85059913846153,{"y":86.1904824,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,68.772,69.29638869729231,69.82077739458462,70.34516609187693,70.86955478916923,71.39394348646154,71.91833218375385,72.44272088104616,72.96710957833847,73.49149827563078,74.01588697292307,74.54027567021538,75.06466436750769,{"y":75.5890530648,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,68.772,68.66532971076924,68.55865942153847,68.4519891323077,68.34531884307692,68.23864855384616,68.13197826461538,68.02530797538462,67.91863768615384,67.81196739692308,67.7052971076923,67.59862681846154,67.49195652923076,{"y":67.38528624,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":68.772,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.772,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetCHF86.19

Average Price TargetCHF75.59

Lowest Price TargetCHF67.39

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Josh Jennings

TD Cowen

CHF76

Buy

10.52%

Upside

Reiterated

04/17/26

Edwards Lifesciences (EW) Gets a Buy from TD Cowen

Anthony Petrone

Mizuho Securities

CHF106.56→CHF74.44

Buy

8.24%

Upside

Assigned

04/13/26

Edwards Lifesciences price target lowered to $95 from $100 at MizuhoEdwards Lifesciences price target lowered to $95 from $100 at Mizuho

Shagun Singh Chadha

RBC Capital

CHF78.35

Buy

13.94%

Upside

Reiterated

04/13/26

RBC Capital Sticks to Their Buy Rating for Edwards Lifesciences (EW)

Joanne Wuensch

Citi

CHF79.14

Buy

15.08%

Upside

Reiterated

04/07/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Edwards Lifesciences (NYSE: EW), Alcon (NYSE: ALC) and Elanco Animal Health (NYSE: ELAN)

Vijay Kumar

Evercore ISI

CHF73.65→CHF72.09

Buy

4.82%

Upside

Assigned

04/06/26

Edwards Lifesciences price target lowered to $92 from $94 at Evercore ISIEdwards Lifesciences price target lowered to $92 from $94 at Evercore ISI

Michael Polark

Wolfe Research

CHF72.09

Buy

4.82%

Upside

Upgraded

04/01/26

Edwards Lifesciences (EW) was upgraded to a Buy Rating at Wolfe Research

Robbie Marcus

J.P. Morgan

―

Buy

―

Reiterated

03/30/26

Edwards Lifesciences: TRISCEND II Data and EVOQUE Differentiation Underpin Buy Rating and Long-Term Growth Outlook

Matthew Taylor

Jefferies

CHF79.92

Buy

16.22%

Upside

Reiterated

03/16/26

Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Plus Therapeutics (PSTV)

Matt Miksic

Barclays

CHF81.49

Buy

18.50%

Upside

Reiterated

03/11/26

Barclays Sticks to Its Buy Rating for Edwards Lifesciences (EW)

Marie Thibault

BTIG

CHF80.71

Buy

17.36%

Upside

Reiterated

02/18/26

BTIG Reaffirms Their Buy Rating on Edwards Lifesciences (EW)

Danielle Antalffy

UBS

CHF73.65→CHF70.52

Hold

2.54%

Upside

Reiterated

02/12/26

Edwards Lifesciences price target lowered to $90 from $94 at UBSEdwards Lifesciences price target lowered to $90 from $94 at UBS

Patrick Wood

Morgan Stanley

CHF67.39

Hold

-2.01%

Downside

Reiterated

02/12/26

Edwards Lifesciences (EW) Receives a Hold from Morgan Stanley

Adam Maeder

Piper Sandler

CHF76.79→CHF78.35

Buy

13.94%

Upside

Reiterated

02/11/26

Piper Sandler Sticks to Its Buy Rating for Edwards Lifesciences (EW)

Suraj Kalia

Oppenheimer

―

Hold

―

Reiterated

02/11/26

Richard Newitter

Truist Financial

CHF72.09→CHF69.74

Hold

1.40%

Upside

Reiterated

02/11/26

Truist Financial Keeps Their Hold Rating on Edwards Lifesciences (EW)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Josh Jennings

TD Cowen

CHF76

Buy

10.52%

Upside

Reiterated

04/17/26

Edwards Lifesciences (EW) Gets a Buy from TD Cowen

Anthony Petrone

Mizuho Securities

CHF106.56→CHF74.44

Buy

8.24%

Upside

Assigned

04/13/26

Edwards Lifesciences price target lowered to $95 from $100 at MizuhoEdwards Lifesciences price target lowered to $95 from $100 at Mizuho

Shagun Singh Chadha

RBC Capital

CHF78.35

Buy

13.94%

Upside

Reiterated

04/13/26

RBC Capital Sticks to Their Buy Rating for Edwards Lifesciences (EW)

Joanne Wuensch

Citi

CHF79.14

Buy

15.08%

Upside

Reiterated

04/07/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Edwards Lifesciences (NYSE: EW), Alcon (NYSE: ALC) and Elanco Animal Health (NYSE: ELAN)

Vijay Kumar

Evercore ISI

CHF73.65→CHF72.09

Buy

4.82%

Upside

Assigned

04/06/26

Edwards Lifesciences price target lowered to $92 from $94 at Evercore ISIEdwards Lifesciences price target lowered to $92 from $94 at Evercore ISI

Michael Polark

Wolfe Research

CHF72.09

Buy

4.82%

Upside

Upgraded

04/01/26

Edwards Lifesciences (EW) was upgraded to a Buy Rating at Wolfe Research

Robbie Marcus

J.P. Morgan

―

Buy

―

Reiterated

03/30/26

Edwards Lifesciences: TRISCEND II Data and EVOQUE Differentiation Underpin Buy Rating and Long-Term Growth Outlook

Matthew Taylor

Jefferies

CHF79.92

Buy

16.22%

Upside

Reiterated

03/16/26

Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Plus Therapeutics (PSTV)

Matt Miksic

Barclays

CHF81.49

Buy

18.50%

Upside

Reiterated

03/11/26

Barclays Sticks to Its Buy Rating for Edwards Lifesciences (EW)

Marie Thibault

BTIG

CHF80.71

Buy

17.36%

Upside

Reiterated

02/18/26

BTIG Reaffirms Their Buy Rating on Edwards Lifesciences (EW)

Danielle Antalffy

UBS

CHF73.65→CHF70.52

Hold

2.54%

Upside

Reiterated

02/12/26

Edwards Lifesciences price target lowered to $90 from $94 at UBSEdwards Lifesciences price target lowered to $90 from $94 at UBS

Patrick Wood

Morgan Stanley

CHF67.39

Hold

-2.01%

Downside

Reiterated

02/12/26

Edwards Lifesciences (EW) Receives a Hold from Morgan Stanley

Adam Maeder

Piper Sandler

CHF76.79→CHF78.35

Buy

13.94%

Upside

Reiterated

02/11/26

Piper Sandler Sticks to Its Buy Rating for Edwards Lifesciences (EW)

Suraj Kalia

Oppenheimer

―

Hold

―

Reiterated

02/11/26

Richard Newitter

Truist Financial

CHF72.09→CHF69.74

Hold

1.40%

Upside

Reiterated

02/11/26

Truist Financial Keeps Their Hold Rating on Edwards Lifesciences (EW)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Edwards Lifesciences

3 Months

xxx

Success Rate

16/25 ratings generated profit

Average Return

+1.29%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.00% of your transactions generating a profit, with an average return of +1.29% per trade.

1 Year

Jayson BedfordRaymond James

Success Rate

17/25 ratings generated profit

Average Return

+11.34%

Copying Jayson Bedford's trades and holding each position for 1 Year would result in 68.00% of your transactions generating a profit, with an average return of +11.34% per trade.

2 Years

xxx

Success Rate

15/25 ratings generated profit

Average Return

+16.37%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of +16.37% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EW Analyst Recommendation Trends

Rating

Dec 25

Jan 26

Feb 26

Mar 26

Apr 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, EW has received 24 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. EW average Analyst price target in the past 3 months is 75.59.

Each month's total comprises the sum of three months' worth of ratings.

EW Financial Forecast

EW Earnings Forecast

Next quarter’s earnings estimate for EW is CHF0.57 with a range of CHF0.55 to CHF0.59. The previous quarter’s EPS was CHF0.45. EW beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year EW has Performed in-line its overall industry.

EW Sales Forecast

Next quarter’s sales forecast for EW is CHF1.25B with a range of CHF1.22B to CHF1.27B. The previous quarter’s sales results were CHF1.23B. EW beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year EW has Performed in-line its overall industry.

EW Stock Forecast FAQ

What is CH:EW’s average 12-month price target, according to analysts?

Based on analyst ratings, Edwards Lifesciences’s 12-month average price target is 75.59.

What is CH:EW’s upside potential, based on the analysts’ average price target?

Edwards Lifesciences has 9.92% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Edwards Lifesciences a Buy, Sell or Hold?

Edwards Lifesciences has a consensus rating of Moderate Buy, which is based on 16 buy ratings, 6 hold ratings and 0 sell ratings.

What is Edwards Lifesciences’s share price target?

The average share price target for Edwards Lifesciences is 75.59. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF86.19 ,and the lowest forecast is CHF67.39. The average share price target represents 9.92% Increase from the current price of CHF68.77.

What do analysts say about Edwards Lifesciences?

Edwards Lifesciences’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 22 Wall Streets Analysts.

How can I buy shares of Edwards Lifesciences?

To buy shares of CH:EW, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Edwards Lifesciences (EW) Stock Forecast & Price Target

EW Analyst Ratings

EW Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Edwards Lifesciences

EW Analyst Recommendation Trends

EW Financial Forecast

EW Earnings Forecast

EW Sales Forecast

EW Stock Forecast FAQ

Detailed List of Analyst Forecasts